MULTRYS (cupric sulfate)
Multrys is a combination of four trace elements (zinc, copper, manganese, and selenium) indicated for neonatal and pediatric patients weighing less than 10 kg. It serves as a source of these essential minerals for parenteral nutrition when oral or enteral nutrition is impossible, insufficient, or contraindicated. The supplement ensures the maintenance of serum mineral levels required for critical biological processes in patients who cannot achieve adequate nutritional intake through the digestive tract.
How MULTRYS Works
Multrys provides essential trace elements that function as critical cofactors and catalysts in various biochemical pathways: * **Zinc:** Functions as a cofactor for numerous enzymes, including DNA and RNA polymerases, and is essential for protein structural folding and the activation of substrates like carbonic anhydrase. * **Copper:** Acts as a cofactor for metalloenzymes (such as cytochrome C oxidase and lysyl oxidase) that serve as oxidases to achieve the reduction of molecular oxygen. * **Manganese:** Essential for the catalytic activity of metalloenzymes, including manganese superoxide dismutase and arginase, and contributes to the function of various enzyme families like oxidoreductases and transferases. * **Selenium:** Converted in vivo to hydrogen selenide, which facilitates the formation of selenoproteins (such as glutathione peroxidase and iodothyronine deiodinase) involved in antioxidant defense and
Details
- Status
- Prescription
- First Approved
- 2020-07-02
- Patent Cliff
- 2041
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
Companies
MULTRYS Approval History
What MULTRYS Treats
1 FDA approvalsOriginally approved for its first indication in 2020 .
- Other (1)
MULTRYS Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MULTRYS FDA Label Details
Indications & Usage
FDA Label (PDF)Multrys is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Multrys is a combination of trace elements (zinc sulfate, cupric sulfate, manganese sulfate, and selenious acid) indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
MULTRYS Patents & Exclusivity
Patents (5 active)
Pro Intelligence Preview
Deep insights for MULTRYS
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2041
- • 15 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.